Artera
First company with FDA-cleared AI pathology tests that predict treatment benefit (prostate 2025, breast 2026).
ArteraAI Prostate (de novo 2025), ArteraAI Breast (May 2026); trained on phase 3 trial cohorts.
The first AI tool cleared by the FDA to predict both prognosis and treatment benefit from a routine biopsy slide, in prostate cancer.
An FDA-cleared AI test (May 2026) that reads breast cancer slides to estimate recurrence risk in early hormone-positive disease.
Pages like this
not linked directly; found by shared links- IdeaWhole-patient digital twins validated in prospective randomised trials
Shares Patient-level multimodal foundation models for treatment selection, Pathology & radiology foundation models, Digital pathology & AI, AI that is built but not validated or deployed.
- IdeaA registry of external validation datasets for cancer AI models, with mandatory reporting
Shares Patient-level multimodal foundation models for treatment selection, Pathology & radiology foundation models, Digital pathology & AI, AI that is built but not validated or deployed.
- PairingAI pathology → androgen deprivation duration
Shares ArteraAI Prostate, Digital pathology & AI, Prostate cancer.
- IdeaA federated learning consortium of cancer centres that jointly own the models
Shares Patient-level multimodal foundation models for treatment selection, Pathology & radiology foundation models, Digital pathology & AI, AI that is built but not validated or deployed.
- IdeaContinuous prospective validation for every oncology AI tool after deployment
Shares Pathology & radiology foundation models, Digital pathology & AI, AI that is built but not validated or deployed.
- IdeaDigitise the nation's pathology slides and link them to outcomes
Shares Pathology & radiology foundation models, Digital pathology & AI, AI that is built but not validated or deployed.
- IdeaA pre-competitive consortium to train a shared multimodal cancer foundation model
Shares Patient-level multimodal foundation models for treatment selection, Pathology & radiology foundation models, Digital pathology & AI, AI that is built but not validated or deployed.
- IdeaAI second reads to stop borderline lesions being upgraded to cancer
Shares Pathology & radiology foundation models, Digital pathology & AI, AI that is built but not validated or deployed.